Premium
Construction of a Single‐Atom Nanozyme for Enhanced Chemodynamic Therapy and Chemotherapy
Author(s) -
Liu Yong,
Yao Mei,
Han Wenxiu,
Zhang Huairong,
Zhang Shusheng
Publication year - 2021
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202102016
Subject(s) - catalysis , biophysics , tumor microenvironment , in vivo , combinatorial chemistry , drug delivery , doxorubicin , materials science , radical , biocompatible material , enzyme , chemotherapy , chemistry , nanotechnology , cancer research , biochemistry , biomedical engineering , tumor cells , biology , medicine , surgery , microbiology and biotechnology
To fulfill the demand of precision and personalized medicine, single‐atom catalysts (SACs) have emerged as a frontier in biomedical fields due to enzyme‐mimic catalysis. Herein, we present a biocompatible and versatile nanoagent consisting of single‐atom iron‐containing nanoparticles (SAF NPs), DOX and A549 cell membrane (CM). The designed porous iron‐based SACs originally served as a drug‐carrying nanoplatform to release DOX selectively in a tumor microenvironment (TME) for chemotherapy (CT) due to their high loading capacity (155 %) for DOX; this signifies that SACs are promising candidates for universal cargo delivery. Besides, the designed single‐atom nanoagent can perform like peroxidase, which effectively triggers an in situ tumor‐specific Fenton reaction to generate abundant toxic hydroxyl radicals (⋅OH) selectively in the acidic TME for chemodynamic therapy (CDT). With the combination of CDT and CT, the constructed SAF NPs@DOX@CM nanoagent demonstrates better in vivo therapeutic performance than single‐pathway therapy. In the meantime, after modification with CM, SAF NPs@DOX@CM can achieve homologous binding to target tumor tissues and avoid early clearance. This study presents a type of multifunctional SACs for enhanced cancer treatment via the capacity of a drug carrier combined with the enzymatic therapies of single‐atom catalytic sites.